期刊文献+

卡格列净联合胰岛素治疗肥胖2型糖尿病的效果及对胰岛素抵抗、脂质代谢的影响 被引量:1

Effect of canagliflozin combined with insulin in the treatment of obese type 2 diabetes mellitus and its influences on insulin resistance and lipid metabolism
下载PDF
导出
摘要 目的探讨卡格列净联合胰岛素治疗肥胖2型糖尿病(T2DM)的效果及对胰岛素抵抗、脂质代谢的影响。方法选取2019年1月至2021年10月收治的80例肥胖T2DM患者作为研究对象,按照随机数字表法将其分为对照组和观察组,各40例。两组均给予常规治疗,对照组在常规治疗基础上给予胰岛素治疗,观察组在对照组基础上给予卡格列净治疗。比较两组的治疗效果。结果治疗后,观察组的平均血糖波动幅度(MAGE)、日间血糖平均绝对差(MODD)、72 h血糖水平标准差(SDBG)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、三酰甘油(TG)、载脂蛋白B(ApoB)、低密度脂蛋白胆固醇(LDL-C)水平、腰围(WC)、体质指数(BMI)、内脏脂肪面积(VFA)低于对照组,胰岛β细胞功能指数(HOMA-β)、胰岛素敏感指数(ISI)高于对照组(P<0.05)。结论卡格列净联合胰岛素治疗肥胖T2DM能提高血糖控制效果,减轻胰岛素抵抗,改善脂质代谢,值得推广。 Objective To explore the effect of canagliflozin combined with insulin in the treatment of obese type 2 diabetes mellitus(T2DM)and its influences on insulin resistance and lipid metabolism.Methods A total of 80 obese T2DM patients admitted from January 2019 to October 2021 were selected as the research objects and divided into control group and observation group according to the random number table method,with 40 cases in each group.Both groups were given routine treatment,the control group was treated with insulin on the basis of routine treatment,and the observation group was treated with canagliflozin on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the mean amplitude of glycemic excursions(MAGE),mean of daily differences(MODD),72 h standard deviation of blood glucose(SDBG),homeostasis model assessment of insulin resistance(HOMA-IR),total cholesterol(TC),triacylglycerol(TG),apolipoprotein B(ApoB),low density lipoprotein cholesterol(LDL-C)levels,waist circumference(WC),body mass index(BMI)and visceral fat area(VFA)in the observation group were lower than those in the control group,while the homeostasis model assessment ofβcell function index(HOMA-β)and insulin sensitivity index(ISI)were higher than those of the control group(P<0.05).Conclusion Canagliflozin combined with insulin in the treatment of obese T2DM can promote the effect of blood glucose control,reduce insulin resistance and improve lipid metabolism,which is worthy of promotion.
作者 何晓雅 李海滨 HE Xiaoya;LI Haibin(Endocrinology Department,Qishan County Hospital,Baoji 722400,China)
出处 《临床医学研究与实践》 2023年第30期53-56,共4页 Clinical Research and Practice
关键词 卡格列净 胰岛素 肥胖2型糖尿病 胰岛素抵抗 脂质代谢 canagliflozin insulin obese type 2 diabetes mellitus insulin resistance lipid metabolism
  • 相关文献

参考文献13

二级参考文献123

  • 1薛月华,游利,谢匡成,巫协宁,张黎明,徐晓寅.2型糖尿病患者绝经期骨密度与甲状旁腺素、雌激素相关性研究[J].中国骨质疏松杂志,2006,12(3):236-238. 被引量:5
  • 2HortonES, SilbermanC, DavisKL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database[J].Diabetes Care, 2010, 33(8):1759-1765. DOI: 10.2337/dc09-2062.
  • 3BaruahMP, ChaudhuryT, SethiBK, et al. Liraglutide in type 2 diabetes mellitus[J].J Indian Med Assoc, 2012, 110(5):335-338.
  • 4de WitHM, VervoortGM, JansenHJ, et al. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreasesinsulin dose in patients with type 2 diabetes:a 26 week, randomised clinical trial (ELEGANT)[J]. Diabetologia, 2014, 57(9):1812-1819. DOI: 10.1007/s00125-014-3302-0.
  • 5CerielloA, SportielloL, RafanielloC, et al. DPP-4 inhibitors: pharmacological differences and their clinical implications[J]. Expert Opin Drug Saf, 2014, 13(9):57-68. DOI: 10.1517/14740338.2014.944862.
  • 6KimMH, LeeMK. The incretins and pancreatic beta-cells: use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus[J]. Korean Diabetes J, 2010, 34(1):2-9. DOI: 10.4093/kdj.2010.34.1.2.
  • 7LiCJ, LiJ, ZhangQM, et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J].Cardiovasc Diabetol, 2012, 15(11):134-142. DOI: 10.1186/1475-2840-11-142.
  • 8KuhadiyaND, MalikR, BelliniNJ, et al.Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus[J]. Endocr Pract, 2013, 19(6):963-967. DOI: 10.4158/EP13065.OR.
  • 9Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 [ N/OL]. Available at: http://www, cdc. gov/diabetes/pubs/ statsreport 14/national-diabetes-report -web. pdf.
  • 10Yu Xu, LiminWang, et al. Prevalence and Control of Diabetes in Chinese Adults[J]. JAMA, 2013,310(9) :948-959.

共引文献512

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部